cyclophosphamide + dexamethasone + rituximab

The combination of cyclophosphamide, dexamethasone, and rituximab—commonly referred to as DRC or RCD—is an immunochemotherapy regimen used primarily in the treatment of indolent B-cell lymphoproliferative disorders such as Waldenström macroglobulinemia (WM) and for immune cytopenias associated with chronic lymphocytic leukemia (CLL), including autoimmune hemolytic anemia (AIHA) and idiopathic thrombocytopenic purpura (ITP)[1][2][3][5][7]. - **Cyclophosphamide** is an alkylating agent that crosslinks DNA, leading to cell death in rapidly dividing cells. - **Dexamethasone** is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive effects. - **Rituximab** is a monoclonal antibody targeting CD20 on B lymphocytes, resulting in their depletion through complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This regimen exploits the synergistic effects of these agents to suppress abnormal B-cell proliferation and modulate immune responses[1][3][5]. It is valued for its efficacy, manageable toxicity profile, and suitability for elderly or frail patients[5].

Brand names

None

Other names

DRCRCD